Abemaciclib Slows Progression of Advanced Liposarcoma

Published Date: 02 Jun 2026

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Read Full News

Latest News

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

Todays Updates

Younger Children With VTE: High Economic & Mortality Burden

Children and adolescents with venous thromboembolism, particularly children aged 4 years or younger, face a higher risk for mortality and economic burden.

Sugammadex Linked to Lower Respiratory Risks After Endoscopy

Block reversal using sugammadex is associated with better respiratory outcomes than that using neostigmine in adults undergoing upper gastrointestinal endoscopic procedures, a study finds.

Todays Updates

Younger Children With VTE: High Economic & Mortality Burden

Children and adolescents with venous thromboembolism, particularly children aged 4 years or younger, face a higher risk for mortality and economic burden.

Sugammadex Linked to Lower Respiratory Risks After Endoscopy

Block reversal using sugammadex is associated with better respiratory outcomes than that using neostigmine in adults undergoing upper gastrointestinal endoscopic procedures, a study finds.

Latest News

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

News All Time

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Recommended News For You

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

Study suggests exercise could reduce breast cancer recurrence

Can certain food cravings predict a cancer diagnosis up to three months before other symptoms appear?

For the first time in humans, a chemotherapy drug reaches the brain.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations

Glioblastoma treatment breakthrough shows promise

Recommended Articles For You

Advanced Directions in Oncology and Quality Improvement 

Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment 

Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data 

Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Accurately identified high-grade prostate cancer through urine testing.

2.

Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.

3.

Abemaciclib Slows Progression of Advanced Liposarcoma

4.

Detecting pancreatic cancer through changes in body composition and metabolism

5.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

1.

Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer

2.

Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine

3.

Decoding the Future: Cancer Genomics and Radiomics in Oncology

4.

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer

5.

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

2.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

3.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

4.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

5.

Updates on Standard V/S High Risk Myeloma Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot